Golden
Synosia Therapeutics

Synosia Therapeutics

A company developing therapies for psychological and neurological illnesses

Synosia Therapeutics is a biotechnology company developing therapies for psychological and neurological illnesses that is headquartered in Basel, Switzerland and was founded in 2006.

Funding

Series A

On March 6, 2006 Synosia Therapeutics completed their series A funding round with $2.5 million in capital from undisclosed investors. 

Venture round

On January 5, 2007 Synosia Therapeutics completed a venture capital round with $32.5 million in funding from Versant Ventures, Novo Holdings, Abingworth, and 5AM Ventures. 

Series B

On January 1, 2009 Synosia Therapeutics completed their series B funding round with $29 million in funding from Investor Growth Capital Limited (lead investor), Aravis Ventures (lead investor), Versant Ventures, Swiss Helvetia Fund, Novo Ventures, Abingworth, and 5AM Ventures. 

Series C

On October 12, 2010 Synosia Therapeutics completed their series C funding round with $30 million in funding from UCB Pharma (lead investor), Versant Ventures, Swiss Halvetia Fund, Novo Holdings, Investor Growth Capital Limited, Aravis Ventures, and 5AM Ventures. 

Timeline

Funding rounds

3 Results

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date

BioTie Therapies Corp. to Acquire CNS Therapeutics Firm Synosia Therapeutics in $121.5M All-Shares Deal

BioSpace

Web



Synosia Therapeutics Raises $30M in Series C Financing

FierceBiotech

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References